# Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

Source: https://onco.cc/trials/nct04099251/  
OnCo record `nct04099251` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Nivolumab in melanoma, run by Bristol-Myers Squibb, active and no longer recruiting.

## Summary

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma is a phase 3 interventional study registered as NCT04099251 by Bristol-Myers Squibb, with 790 participants enrolled, started 2019-10-28 and due to reach its primary completion in 2022-06-28. Interventions recorded: Nivolumab, Placebo. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04099251
- Phase: 3
- Setting: A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Nivolumab Versus Placebo After Complete Resection of Stage IIB/C Melanoma
- Sponsor: Bristol-Myers Squibb
- Enrolled: 790

## Sources

- ClinicalTrials.gov NCT04099251: https://clinicaltrials.gov/study/NCT04099251

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct04099251.json